Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07276802 · ClinicalTrials.gov registry record · Phase 4
The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)
A Phase 4 study, sponsored by Research Insight.
- Not yet
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT07276802 is a Phase 4 study that has not yet begun recruiting, run by Research Insight. The registered enrollment target is 40 participants.
The verdict
NCT07276802, a Phase 4 study, has not yet begun recruiting, sponsored by Research Insight.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.
Interventions
- DRUG control group
- DRUG Triamcinolone (Optional)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07276802
The ClinicalTrials.gov registry entry for NCT07276802 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Research Insight, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which control group is the first listed.
NCT07276802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07276802 about?
NCT07276802 is a clinical study titled "The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)". A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, an...
What is the current status of trial NCT07276802?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2026-04-01. Estimated completion is 2027-01-31.
What interventions are being tested in trial NCT07276802?
The interventions under investigation include: control group (DRUG), Triamcinolone (Optional) (DRUG).
Who is sponsoring clinical trial NCT07276802?
This trial is sponsored by Research Insight, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.